Trials / Completed
CompletedNCT00650767
A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to further evaluate the safety of the study drug. Approximately 200 patients from the US, Argentina, Brazil, Hungary, Peru, Poland and Romania will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-438162, MEK inhibitor; oral | multiple dose, single schedule |
| DRUG | Placebo; oral | matching placebo |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-04-02
- Last updated
- 2020-12-01
- Results posted
- 2016-11-07
Locations
35 sites across 7 countries: United States, Argentina, Brazil, Hungary, Peru, Poland, Romania
Source: ClinicalTrials.gov record NCT00650767. Inclusion in this directory is not an endorsement.